Introduction
West syndrome is a typical infantile spasm that occurs in the first year of life. West syndrome is characterized by a triad of epileptic spasms, often in clusters, arrest of psychomotor development or intellectual disability and an interictal EEG pattern termed hypsarrhythmia, although this diagnosis can be made even if one of the three elements is missing (Lux and Osborne, 2004) . Cerebral atrophy or dysgenesis, such as lissencephaly and hydrocephalus are frequently observed in individuals with West syndrome. Like other paediatric epileptic syndromes, genetic and environmental factors are thought to be associated with West syndrome. Recent studies indicate that mutations have been found in West syndrome of various genes including ARX, CDKL5, FOXG1, GRIN1, GRIN2A, MAGI2, MEF2C, SLC25A22, SPTAN1, and STXBP1, which play essential roles during brain development (Strømme et al., 2002; Kato et al., 2003; Lux and Osborne, 2004; Weaving et al., 2004; Marshall et al., 2008; Saitsu et al., 2008 Saitsu et al., , 2010 Molinari et al., 2009; Ding et al., 2010; Endele et al., 2010; Le Meur et al., 2010; Nowakowska et al., 2010; Brunetti-Pierri et al., 2011) . These facts strongly suggest that disturbances of cortical structure, synaptic function and connectivity during corticogenesis underlie the pathophysiological mechanism of West syndrome.
Phosphatase and actin regulators (PHACTRs) are a family of proteins composed of four members (PHACTR1-4) with distinct expression patterns in the embryonic and adult brain (Allen et al., 2004) . Each member is composed of an N-terminal region containing a nuclear localization signal and an RPEL region, and a C-terminus containing additional three RPEL regions and a protein phosphatase 1 (PP1)-binding domain (Fig. 1) . The RPEL region interacts with G-actin and is considered to have crucial roles in the regulation of cell morphology and motility by modulating the intracellular localization of PHACTRs (Sagara et al., 2009; Wiezlak et al., 2013) . PHACTR1 is expressed in cortical neurons throughout brain development and detected biochemically in the synaptosomal and postsynaptic density fractions (Ito et al., 2018) . PHACTR3 is expressed in the mouse cerebral cortex at moderate levels (Allen et al., 2004) , and regulates axon elongation by modulating actin dynamics (Farghaian et al., 2011 ). PHACTR4 appears to be enriched in proliferating neuroepithelial cells and is involved in neural tube development by regulating the cell cycle (Kim et al., 2007) . Thus PHACTRs participate in neuronal development and function by modulating actin cytoskeleton structure and PP1 activity.
PHACTRs have been also shown to play important roles in non-neuronal cells. PHACTR1 has been implicated in melanoma progression and early-onset myocardial infarct (Smith et al., 2005; Koh et al., 2009; Myocardial Infarction Genetics Consortium et al., 2009) . PHACTR1 was then shown to play a key role in the angiogenesis by modulating PP1 activity and fine-tuning actin dynamics (Allain et al., 2012) . PHACTR3 affects tumour cell morphology by actin remodelling and PP1 signalling (Sagara et al., 2009) . Taken together, it appears that each PHACTR member is likely to have unique cell type-and developmental stage-specific functions, although their functional significance has just begun to be elucidated at the molecular level.
As for the pathophysiological significance of PHACTR1 in neurodevelopmental disorders, three de novo missense mutations have been reported in three individuals. The mutation c.1561C 4 T/p.(Arg521Cys) was identified in a female with infantile epilepsy under good control with antiepileptic drugs and with severe deteriorating psychomotor delay (de Ligt et al., 2012) . Clinical information on a second mutation c.1553T 4 A/p.(Ile518Asn), which was identified in a female with an undiagnosed developmental disorder, has not been available (The Deciphering Developmental Disorders Study, 2017) . Finally, the mutation c.1148C 4 T/p.(Ser383Leu) has been reported in an individual with severe intellectual disability, attention deficit hyperactivity disorder and inability to stand and walk, although this patient also carried the mutation c.2048G 4 A/p.(Arg683His) in CPT1B, which encodes carnitine palmitoyltransferase 1B (Riazuddin et al., 2016) . No individuals with similar neurological features have been registered in GeneMatcher database (https://www.genematcher.org/). In the present study, we have identified two unreported mutations in PHACTR1 occurring de novo in distinct individuals with West syndrome. Experiments with acute knockdown and overexpression of mutants revealed that impaired PHACTR1 function is associated with defects in cortical neuron migration and dendritic arbour formation. Electrophysiological analyses further demonstrated a pivotal role for PHACTR1 in excitatory synapses of cortical neurons.
Materials and methods

Ethics statement
The clinical and genetic studies were approved by institutional review boards for medical ethics of Yokohama City University School of Medicine and Showa University School of Medicine (approval number; A140925001and H27-219, respectively) in accordance with the principles of the Declaration of Helsinki, and the Ethical Guidelines for Human Genome/Gene Analysis Research by the Ministry of Education, Culture, Science, and Technology, the Ministry of Health, Labor, and Welfare, and the Ministry of Economy, Trade, and Industry of Japan. Written informed consent was obtained from the parents of the patients. Clinical information and blood samples for gene analysis were obtained from the family members after written informed consent was secured. For mouse experiments, we followed the Fundamental Guidelines for Proper Conduct of Animal Experiments and Related Activity in Academic Research Institution under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan. All protocols for animal handling and treatment were reviewed and approved by the Animal Care and Use Committee of Institute for Developmental Research, Aichi Human Service Center (approval number, M-10).
Subjects
We analysed 210 trio-families and 490 individuals with earlyonset or developmental and epileptic encephalopathies. Clinical information and peripheral blood leucocytes were collected from patients and their parents. DNA was extracted using QuickGene-610L (Fujifilm) according to the manufacturer's instructions.
Whole exome sequencing
Patient DNA was captured with SureSelect Human All Exon V4 or V5 kits (Agilent Technologies) and sequenced on an Illumina HiSeq2000 or 2500 (Illumina) with 101-bp pairedend reads. Image analysis and base calling were performed by sequence control software real-time analysis and CASAVA software v1.8 (Illumina). Reads were aligned to the human reference genome sequence (UCSC hg19, NCBI build 37) using Novoalign (Novocraft Technologies, Jaya, Malaysia). PCR duplicates were excluded using Picard (http://picard.sourceforge.net/). Single nucleotide variants and small insertion/deletions (indels) were identified using the Genome Analysis Toolkit UnifiedGenotyper (DePristo et al., 2011) , and were filtered according to the Broad Institute's best-practice guidelines (version 3). Variants that passed the filters were annotated using ANNOVAR (Wang et al., 2010) . Variant pathogenicity was evaluated by SIFT (http://sift.jcvi.org/), PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), M-CAP (http://bejerano.stanford.edu/mcap/) and CADD (http://cadd. gs.washington.edu/). Conservation of nucleotides was assessed using GERP (http://mendel.stanford.edu/SidowLab/downloads/ GERP/index.html) and PhastCons (http://compgen.cshl.edu/ phast/). Segregation of all candidate variants were examined by Sanger sequencing on an ABI 3130xl Genetic Analyzer (Applied Biosystems) using trio samples (patients and their parents). In families showing de novo variants, parentage was confirmed by analysing 12 microsatellite markers.
Plasmid construction
Mouse Phactr1, Phactr3 and Phactr4 cDNAs were amplified by RT-PCR with adult mouse brain RNA pools, and cloned into pCAG-Myc vector (Addgene) The following target sequences were inserted into pSuper-puro RNAi vector (OligoEngine): Phactr1#1, GAACTCAATGAGTTTAAAA (1666-1684); Phactr1#2, GGAAGATTTCGATGAGGCA (426-444); Phactr1#3, . Numbers indicate the positions from translational start sites. For the control experiments, we used pSuper-H1.shLuc designed against luciferase (CGTACGCGGAATACTTCGA) (Hamada et al., 2015 (Hamada et al., , 2017 . For an RNAi-resistant version of Phactr1, Phactr1-R, seven silent mutations were introduced in the target sequence as underlined (GAGTTAAACGAA TTCAAGA in Phactr1#1). With pCAG-Myc-Phactr1-R as a template, site-directed mutagenesis was performed with KOD-Plus Mutagenesis kit (Toyobo) to generate four mouse 
Antibodies
Mouse monoclonal anti-Myc (#192-3) and polyclonal rabbit anti-GFP (#598) were from MBL. Polyclonal rabbit antibodies against Myc-tag, SEPT11 (a cytoskeleton-related protein) and PHACTR1 were prepared as described (Hanai et al., 2004; Ito et al., 2018) . Rabbit polyclonal anti-RFP (red fluorescent protein) and anti-Ki67 were from Rockland Immunochemicals. (#600-401-379) and Thermo Fisher Scientific (#RB-1510-P0), respectively. Mouse monoclonal anti-actin was purchased from Cell Signaling Technology (#3700). Cell culture, transfection and immunofluorescence COS7 cells were cultured and transfected with Lipofectamine TM 2000 (Life Technologies) as described (Nagata et al., 2009; Hamada et al., 2016) . Mouse primary cortical neurons were electroporated at embryonic Day 14 (E14) in utero and then cultured in vitro. Immunofluorescence analyses were done as described (Ito et al., 2010; Inaguma et al., 2016) . Alexa Fluor Õ 488-or 568-labelled IgG (Life Technologies) was used as a secondary antibody. 4 0 ,6-diamidino-2-phenylindole (DAPI) was used for DNA staining. Fluorescent images were captured using FV-1000 confocal laser microscope (Olympus).
In utero electroporation
In utero electroporation was performed with pregnant ICR mice essentially as previously described (Tabata and Nakajima, 2001; Hamada et al., 2017) . Briefly, indicated amounts of pCAG expression and pSuper RNAi vectors were injected in various combinations with pCAG-EGFP or pCAG-RFP (0.5 mg each) into the lateral ventricle of embryonic day (E) 14.5 embryos, followed by electroporation using CUY21 electroporator (NEPA Gene) with 50 ms of 35 V electronic pulse for five times with 450 ms intervals. As for quantitative analyses of neuronal migration, distribution of GFP-or RFPpositive cells was quantified by calculation of the number of labelled cells in each region of the brain slices.
EdU incorporation experiments
Embryos were electroporated with pCAG-EGFP together with control pSuper-H1.shLuc, pSuper-Phactr1#1, pCAG-MycPhactr1, -Phactr1-LP or -Phactr1-RC in utero at E14. 5-Ethynyl-2 0 -deoxyuridine (EdU) injection (25 mg/kg body weight) was done at 24 h after electroporation. Then, after 24 h brains were sectioned and subjected to staining for EdU, Ki67 and GFP. The ratio of EdU/Ki67/GFP-triple positive cells to EdU/GFP-double positive cells was determined.
Electrophysiological analyses
Detailed experimental procedures of the whole cell recording have been described previously (Sasaki et al., 2010; Hamada et al., 2016; Nishijo and Momiyama, 2016) . In brief, a brain slice obtained from control or Phactr1-knockdown mouse was superfused for recording with standard Krebs solution of the following composition (mM): NaCl, 124; KCl, 3; NaHCO 3 , 26; NaH 2 PO 4 , 1; CaCl 2 , 2.4; MgCl 2 , 1.2; D-glucose, 10; pH 7.4, bubbled with 95% O 2 + 5% CO 2 ) in a recording chamber. Fluorescent pyramidal neurons in the layer II were displayed on a video monitor and used for whole-cell recording with a patch-clamp amplifier (Axopatch 200B, Molecular Devices). The cell capacitance and the series resistance were measured from the amplifier. The access resistance was monitored by measuring capacitative transients obtained in response to a hyperpolarizing voltage step (5 mV, 25 ms) from a holding potential of À60 mV. No correction was made for the liquid junction potentials (calculated to be 5.0 mV by pCLAMP7 software, Molecular Devices). Synaptic currents were evoked at a rate of 0.2 Hz (every 5 s) by extracellularly delivered voltage pulses (0.2-0.4 ms duration) of suprathreshold intensity via a stimulating electrode. The stimulating electrode was placed within 50-120 mm radius of the recorded neuron. The position of the stimulating electrode was varied until a stable response was evoked in the recorded neuron. Experiments were carried out at room temperature.
Data were stored on digital audio tapes. Evoked excitatory postsynaptic currents (EPSCs) were digitized off-line at 10 kHz (low-pass filtered at 2 kHz with an 8-pole Bessel filter) using pCLAMP9 software (Molecular Devices). The effects of drugs on the evoked EPSCs were assessed by averaging their amplitudes for 100 s (20 traces) after the effect had reached the steady state and comparing this value with the averaged amplitude of 20 traces just before the drug application.
Statistical analysis
Results were expressed as means AE SD except for the physiological analyses where results were expressed as means AE SEM. When data were obtained from only two groups, Student's and Welch's t-test were used for comparison. Sholl radii were analysed using two-way analysis of variance (ANOVA) followed by a post hoc Student's and Welch's t-test. For other experiments, the rate of cell scores was initially analysed using the one-way ANOVA. Subsequently, Tukey-Kramer least significant difference (LSD) test was applied to absolute values as a post hoc test of multiple comparisons. The level of statistical significance was considered to be P 5 0.05. Statistical analysis was performed using Statcel3 software (OMS Inc., Tokorozawa, Japan).
Data availability
The data that support the findings of this study are available from the corresponding author, upon reasonable request.
Results
Patient reports
Patient 1 in Family 1 was the third child of non-consanguineous Japanese parents. Polyhydramnios was noticed during pregnancy. He was delivered by caesarean section at 37 weeks of gestation. His birth weight was 2320 g (light for dates, 18th percentile), height was 47.5 cm, and head circumference was 33.5 cm. He attained eye pursuit and social smile at 2 months of age, but could not achieve head control. He started to have epileptic spasms in clusters and independent focal seizures with tonic component at 3 months of age. On physical examination, generalized hypotonia was observed and no apparent malformation except for cryptorchidism was found. Interictal EEG showed hypsarrhythmia. Ictal discharges of high-voltage slow-wave with fast-activities corresponding to epileptic spasms, which were rarely followed by rhythmic -waves originating from right mid-temporal area consistent with focal seizures, were observed ( Supplementary Fig. 1A ). Repeated brain MRI at 3 months and 20 months of age revealed progressive atrophy and delayed myelination ( Supplementary Fig. 1B ). Laboratory examinations and chromosomal karyotype were normal. He was diagnosed as West syndrome. Administrations of pyridoxal phosphate and adrenocorticotropic hormone (ACTH) had no effect. Antiepileptic drugs such as valproic acid, lamotrigine and levetiracetam were not effective for his seizures. A second trial of ACTH injections at 1 year and 6 months of age temporarily aborted the epileptic spasms.
Patient 2 in Family 2 was born at 39 weeks of gestation after uncomplicated pregnancy as the first child of unrelated healthy Japanese parents. His maternal grandfather suffered from epilepsy after brain injury in adult. He gained eye pursuit and social smile at 2 months of age. The patient showed widely spaced eyes, short eyebrows, fullness of upper eyelid and small mouth (Supplementary Fig. 2A ). He started to have epileptic spasms in cluster and hypsarrhythmia on EEG ( Supplementary Fig. 2B ), leading to a diagnosis of West syndrome at 3 months of age. He also had paroxysmal upward gazing with no change of EEG findings. Brain MRI was normal and other laboratory examinations including chromosomal analysis could not unravel the aetiology; his karyotype was 46,XY and fluorescent in situ hybridization (FISH) analysis on chromosome 22q11.2 was normal. Pyridoxal phosphate and valproic acid were ineffective for his seizures, which disappeared after intramuscular ACTH injections. A few months after ACTH treatment, he temporarily showed poor feeding and developmental deterioration, which were improved by changing breast feeding for formula milk. At 12 months of age, he showed brief tonic seizures followed by crying with preceding frontal fast waves on ictal EEG. When clobazam was added on to valproic acid, his seizures disappeared but the EEG findings were unaltered. He walked alone at 18 months of age and started to speak single words at 24 months. He showed autism spectrum disorder (ASD) with severe agitation, which required the administration of risperidone and Yokukansan, a Japanese traditional herbal 'Kampo' medicine. Brain MRI and PET with fluoro-deoxyglucose were normal at 3 years of age.
Clinical features of the two patients are summarized in Supplementary Table 1 .
Mutation screening
Using trio whole-exome sequencing data of 210 families, we searched variants that were consistent with autosomal dominant (de novo) and autosomal or X-linked recessive inheritance. We filtered out common variants with minor allele frequencies 51% in dbSNP 137, the 6500 exomes of the National Heart, Lung, and Blood Institute exome project, and the Exome Aggregation Consortium (ExAC, Cambridge, MA) (Lek et al., 2016) , and variants found in more than five of our in-house 575 control exomes. In Family 1, we found a possible four de novo variants in four genes consistent with the autosomal dominant model, and six compound heterozygous variants in three genes with the recessive models, but only two de novo variants, c.1449T 4 C/p.(Leu500Pro) in PHACTR1 (NM_030 948.2) and c.12435G 4 A/p.(Trp4145*) in STARD9 (NM_020759.2), were predicted to be deleterious (Table 1) . Three de novo variants in PHACTR1 have so far been found in patients with undiagnosed developmental disorders (de Ligt et al., 2012; Riazuddin et al., 2016; The Deciphering Developmental Disorders Study, 2017) . In addition, a homozygous STARD9 variant was found in a patient with syndromic neurodevelopmental disorder (Okamoto et al., 2017) . Considering these findings, we focused on PHACTR1 as a novel candidate gene for neurodevelopmental disorders. Using case-only whole-exome sequencing data in 490 individuals, we searched possible PHACTR1 variants and identified another de novo variant, c.1436A 4 T/p.(Asn479Ile), in Family 2 (Table 2) . Both variants were not found in dbSNP138 data, ExAC or 575 in-house Japanese control exomes. Altered Asn479 and Leu500 residues were both evolutionarily conserved (Fig. 1) . Sanger sequencing confirmed that both variants occurred de novo. Their biological parentage was confirmed.
Characterization of Phactr1 mutations
Because the c.1436A 4 T/p.(Asn479Ile) and c.1449T 4 C/ p.(Leu500Pro) missense mutations are positioned in third and fourth RPEL regions, respectively (Fig. 1) , these Phactr1-NI and Phactr1-LP mutants are likely to have abnormal actin-binding activity leading to abnormal protein function(s). We therefore examined whether the p.Leu500Pro and p.Asn479Ile mutations affect the interaction of PHACTR1 with actin and PP1. We also analysed Table 1 Candidate variants identified by trio whole exome sequencing two additional disease-related mutations, p.Arg521Cys and p.Ile518Asn. Actin-binding activity was dramatically decreased in Phactr1-LP, Phactr1-NI and Phactr1-IN (Fig. 1B and data not shown) , while Phactr1-RC maintained actin-binding ability, despite this mutation being situated in the C-terminal end of fourth RPEL region. This Phactr1-RC mutation, however, lost the ability to bind PP1 (Fig. 1C) . These results suggest that defects in the interaction of PHACTR1 with actin or PP1 are related to the pathophysiology of West syndrome and intellectual disability.
Roles of PHACTR1 in neuronal migration during corticogenesis
Because organized neuronal migration is essential for brain development, we examined the role of PHACTR1 in the migration of newly generated cortical neurons. To this end, we designed three RNAi vectors, pSuper-Phactr1#1-#3 (sh-Phactr1#1-#3), against distinct regions in the mouse Phactr1 coding sequence. These vectors efficiently knocked down exogenous and endogenous PHACTR1 in COS7 cells and cortical neurons, respectively ( Fig. 2A and B) . In COS7 cell expression experiments, they did not affect the expression of PHACTR3 and PHACTR4, which are abundant in the brain, confirming the specificity of these RNAi vectors (Fig. 2C ). pCAG-EGFP was then co-electroporated in utero with 2.0 mg of pSuper-H1.shLuc (control) or sh-Phactr1#1-#3 into the ventricular zone progenitor and stem cells of E14.5 brains. When localization of transfected cells and their progeny was analysed at postnatal Day (P) 0, neurons were found to migrate normally to layers II-IV of the cortical plate in the control experiment [ Fig. 2D(a) and E]. In contrast, cells transfected with sh-Phactr1#1, #2 or #3 frequently showed migration defects and remained in the lower part of cortical plate and intermediate zone [ Fig. 2D(b-d) and E]. In addition, abnormal cell morphology and polarity were prominent for the mispositioned cells [ Fig. 2D(b'-d') ]. When we examined the long-term effects of Phactr1 silencing, the deficient cells still exhibited abnormal positioning at P7 (Fig. 2F) , strongly suggesting that PHACTR1-deficiency prevents, rather than delays, cortical neuron migration. These results suggest that PHACTR1 plays a pivotal role in neuronal migration.
Rescue experiments were then conducted to rule out offtarget effects. To this end, we prepared an RNAi-resistant version of PHACTR1, Phactr1-R, and confirmed that it was resistant to sh-Phactr1#1 in COS7 cells (Fig. 3A) . When pCAG-EGFP (0.5 mg) was electroporated into the ventricular zone cells with sh-Phactr1#1 (1.5 mg) together with pCAG-Myc-Phactr1-R (0.2 mg), the positional defects were significantly rescued at P0 [ Fig. 3B(a, b) and C]. In sharp contrast, the disease-related mutants, Phactr1-LP, Phactr1-NI, Phactr1-RC and Phactr1-IN could not rescue the phenotype under the same conditions [ Fig. 3B(c-f) and C]. PHACTR1 and the mutants were confirmed to be expressed in each experimental condition [ Fig. 3B(b'-f') ]. These results demonstrate the pathophysiological significance of these mutations. It is notable that co-expression of the mutants appeared to produce more defective migration phenotype than simple knockdown of Phactr1, because the cell numbers at the intermediate zone tended to increase when the mutant, especially Phactr1-LP, was coexpressed with sh-Phactr1#1 (Fig. 3C) .
The observations in Fig. 3 suggest that the mutants function as dominant negative versions and abrogate the function of endogenous PHACTR1 under conditions of haploinsufficiency. To test this possibility, we next looked into the effects of simple overexpression of PHACTR1, Phactr1-LP, Phactr1-NI, Phactr1-RC and Phactr1-IN on neuronal migration. As shown in Fig. 4A and B, all four mutants (1.0 mg of each vector), but not the wild-type, caused migration defects. These defects disappeared when amount of each mutant vector electroporated was reduced to 0.5 mg/embryo (Fig. 4C) , suggesting that under these conditions each mutant could not compete sufficiently with endogenous PHACTR1.
When PHACTR1 was silenced in utero with shPhactr1#1 (1.0 mg/embryo), cortical neuron migration was found to be little affected [ Fig. 4D(a) ]. It was, however, noteworthy that electroporation of pCAG-Myc-Phactr1-LP, -NI, -RC or -IN (0.5 mg/embryo) induced migration defects when coelectroporated with sh-Phactr1#1 (1.0 mg) [ Fig. 4D(c-f) and E]. In contrast, co-electroporation of pCAG-Myc-Phactr1 (0.5 mg) under the same condition had no effects on migration [ Fig. 4D(b) and B]. These results strongly suggest that each PHACTR1 mutant competitively inhibits the function of reduced levels of endogenous PHACTR1, and thus exerts dominant negative effects. As in the case of simple knockdown [ Fig. 2D(b'-d') ], the mispositioned neurons at P0 frequently exhibited abnormal morphology such as a branched leading process and impaired cell polarity [ Fig. 4D(c'-f') ]. While these cells with abnormal morphology were suspected to have finished migration, the abnormal branching cell shape was also Error bars indicate SD (Control, n = 5; sh-Phactr1#1, n = 5; sh-Phactr1#2, n = 6; sh-Phactr1#3, n = 6); **P 5 0.01 *P 5 0.05. Statistical elements (median, interquartile intervals, minimum and maximum) are provided in Supplementary Table 2. (F) Migration defects of Phactr1-deficient cortical neurons at P7. Analyses were done as in D. Scale bar = 100 mm.
observed in migrating neurons (at E17) expressing the mutants (Fig. 4F) . Taken together, the four PHACTR1 mutants appear to disrupt cortical neuron migration and cause abnormal cortical architecture in a dominant negative manner.
PHACTR1 is not involved in proliferation of neuronal progenitor and stem cells
Impaired proliferation of neuronal progenitor cells is known to result in migration defects of cortical neurons (Bellenchi et al., 2007; Friocourt et al., 2008; Clément et al., 2017) . We therefore examined the effects of Phactr1-knockdown and overexpression of PHACTR1, Phactr1-LP or Phactr1-RC on the cell cycle exit of ventricular zone/subventricular zone cells by triple staining for EdU, GFP and Ki67, a marker for all active phases of the cell cycle except the quiescent G0 state. In this analysis, cells still in the proliferating state after EdU incorporation could be identified as EdU/Ki67 double-positive while neurons that differentiated after EdU incorporation would be EdU-positive but Ki67-negative. We found no statistical differences in the ratio of EdU/Ki67/GFP triple-positive cells to EdU/GFP double-positive cells between control pCAG-Myc-Phactr1 or -Phactr1-R (0.2 mg each) was transfected into COS7 cells with pSuper-H1.shLuc (Control) or sh-Phactr1#1 (1.5 mg each). Western blotting analyses were done as Fig. 2A. (B) pCAG-RFP was electroporated with sh-Phactr1#1 (1.5 mg) together with pCAG vector (a), pCAG-Myc-Phactr1-R (b), -Phactr1-LP (c), -Phactr1-NI (d), -Phactr1-RC (e) or -Phactr1-IN (f) (0.2 mg each) into E14 embryonic brains, followed by fixation at P0. Coronal sections were stained for RFP (white) and nuclei (blue). PHACTR1 expression in the conditions in b-f was confirmed with anti-Myc in b'-f'), respectively. Scale bars = 100 mm in f and 5 mm in f'. (C) Quantification of the distribution of neurons in distinct regions of the cerebral cortex for each condition in B. Error bars indicate SD [sh-Phactr1#1, n = 6; #1 + Phactr1-R (WT), n = 7; #1 + LP, n = 6; #1 + NI, n = 4; #1 + RC, n = 5; #1 + IN, n = 5]; **P 5 0.01. Statistical elements (median, interquartile intervals, minimum and maximum) are provided in Supplementary Table 2. pCAG-EGFP was co-electroporated into cerebral cortices at E14 with 1 mg of pCAG-Myc-Phactr1 (a), -Phactr1-LP (b), -Phactr1-NI (c), -Phactr1-RC (d) or -Phactr1-IN (e), followed by fixation at P0. Coronal sections were stained for GFP (white) and nuclei (blue). Scale bar = 100 mm. (B) Quantification of the distribution of neurons in distinct regions for each condition in A. Error bars indicate SD [Phactr1(WT), n = 7; Phactr1-LP, n = 9; -NI, n = 8; -RC, n = 6; -IN, n = 4]; *P 5 0.05, **P 5 0.01. (C) pCAG-EGFP was co-electroporated into cerebral cortices at E14 with 0.5 mg of pCAG-Myc-Phactr1-LP (a), -Phactr1-NI (b), -Phactr1-RC (c), or -Phactr1-IN (d), followed by fixation at P0. Coronal sections were stained for GFP (white) and nuclei (blue). Representative images were shown (Phactr1-LP, n = 6; -NI, n = 6; -RC, n = 3; -IN, n = 9). Scale bars = 100 mm. (D) pCAG-EGFP was co-electroporated into cerebral cortices at E14 with sh-Phactr1#1 (1.0 mg) together with 0.5 mg of pCAGMyc vector (a), pCAG-Myc-Phactr1-R (b), -Phactr1-LP (c), -Phactr1-NI (d), -Phactr1-RC (e) or -Phactr1-IN (f), followed by fixation at P0. Coronal sections were stained for GFP (white) and nuclei (blue). Magnified images of neuron morphology (layer IV-VI) in the conditions in c-f were shown as c'-f', respectively. Scale bars = 100 mm. (E) Quantification of the distribution of neurons in distinct regions of the cerebral cortex for each condition in D. Error bars indicate SD [sh-Phactr1#1 + vector, n = 6; #1 + Phactr1-R (WT), n = 6; #1 + LP, n = 9; #1 + NI, n = 7; #1 + RC, n = 8; #1 + IN, n = 5]; **P 5 0.01. (F) Representative images of migrating neurons expressing GFP with sh-Phactr1#1 together with Myc-Phactr1-R (WT), -Phactr1-LP, -Phactr1-NI or -Phactr1-RC. The experiment was carried out as in D, followed by fixation at E17. Coronal sections were stained for GFP. Scale bar = 10 mm. Quantification of neurons with a branched process was performed. More than 150 cells in more than five brains were analysed for each experiment. Error bars indicate SD; **P 5 0.01. Statistical elements (median, interquartile intervals, minimum and maximum) for B, E and F are provided in Supplementary Table 2. and the knockdown cells labelled with GFP [ Supplementary  Fig. 3A(a, b) and B]. The ratio of the triple-positive cells over the double-positive ones in cells expressing PHACTR1 or the two mutants was also similar to that of control cells [ Supplementary Fig. 3A(c-e) and B]. These results strongly suggest that PHACTR1 and the mutations are not involved in the neuronal precursor proliferation at the ventricular zone/subventricular zone.
Role of PHACTR1 in the dendritic arbour development in vivo
Given that aberrant synaptic network formation is linked to defective brain development and function, PHACTR1 may be involved in axon and/or dendrite growth during corticogenesis. First, we analysed the interhemispheric axon projections of Phactr1-deficient cortical neurons in vivo. When Phactr1 was silenced in the ventricular zone cells at E14.5, axon bundles extended normally into the contralateral hemisphere at P0 and P7 (data not shown). These results suggest that PHACTR1 is not involved in the axon extension in vivo.
Next we examined the role of PHACTR1 in dendritic arbour formation. Introduction of sh-Phactr1#1 (1.0 mg) into the ventricular zone cells at E14.5 resulted in highly suppressed dendritic arborization at P7 [ Fig. 5A(a and b) ]. The total length of dendrites was significantly reduced in PHACTR1-deficient neurons compared to that in matching control cells, indicating that PHACTR1 participates in dendritic arbour formation (Fig. 5B) . Although this was rescued by Phactr1-R [ Fig. 5A(c) and B], the mutants Phactr1-LP, Phactr1-NI, Phactr1-RC and Phactr1-IN could not rescue this abnormal phenotype [ Fig. 5A(d-g) and B]. It should be noted that it was difficult to detect Phactr1-LP and Phactr1-IN at P7, perhaps due to protein degradation [ Fig. 5A(d and g, bottom) ], strongly suggesting that the abnormal phenotype produced by these mutants reflected Phactr1 silencing rather than the mutant expression. In contrast, Phactr1-NI and Phactr1-RC could both be visualized, albeit weakly and strongly, respectively, when compared to the wild-type [ Fig. 5A(c, e and f,  bottom) ]. While co-expression of Phactr1-NI with shPhactr1#1 exhibited a phenotype similar to the knockdown phenotype, Phactr1-RC tended to show more severe suppression of dendrite development although the rescue effects were statistically negative (Fig. 5B) . We then focused on the role of the p.Arg521Cys mutation on dendritic development. Co-expression of wild-type Phactr1 rescued the phenotype of Phactr1-RC-expression in terms of the total length of basal dendrites ( Supplementary Fig. 4A and B) . These results suggest that Phactr1-RC may exert dominant negative effects.
When the total dendritic length was measured later at P21, it remained reduced in the deficient neurons ( Fig. 5C  and D) . Branch point number was also decreased in the deficient neurons at P21 (Fig. 5E ). It should be noted that neuronal migration was not affected under the experimental conditions where 1.0 mg of sh-Phactr1#1 was electroporated [ Fig. 4D(a) and E). Thus dendritic development is likely to be more sensitive than neuronal migration to PHACTR1 expression level.
Collectively, functional defects in PHACTR1 are most likely to impair synaptic connectivity through defects in dendritic arbour formation rather than axon elongation. The pathophysiology of West syndrome as well as intellectual disability with PHACTR1 gene abnormalities may reflect these observed cellular phenotypes.
Electrophysiological analyses
PHACTR1 was found to play a crucial role in dendritic development and synaptic network formation. We next examined the role of Phactr1 in synaptic function using electrophysiological methods. We first examined the membrane properties of excitatory cortical neurons. To this end, whole-cell recordings were made from layer II pyramidal neurons (n = 40) from control (n = 18) and Phactr1-knockdown mice (n = 22) at P7-10. Cell capacitance of neurons in control and the knockdown mice were 27.3 AE 0.92 pF (n = 18), and 29.7 AE 1.04 pF (n = 22), respectively. These values are not significantly different (P 4 0.05). The resting membrane potentials of control and the knockdown cells were À51.0 AE 2.73 mV (n = 11) and À55.2 AE 1.68 mV (n = 10), respectively. Again, these are not significantly different (P 4 0.05). On the other hand, the input resistance of the knockdown cells was 253.4 AE 23.3 M (n = 10), which is significantly (P 5 0.05) smaller than that of controls (428.3 AE 41.0 M, n = 8).
We then analysed firing patterns. In the resting state, layer II pyramidal neurons did not fire spontaneous action potentials in either control or the knockdown mice. Firing properties were therefore investigated by applying depolarizing current pulses through the recording pipette in the current-clamp mode. As shown in Fig. 6A and B, the number of action potentials elicited by 50 pA depolarizing current pulses in the knockdown neurons was 1.90 AE 1.13 (n = 10), which is significantly (P = 0.03) lower than that in control cells (7.13 AE 1.72, n = 8).
In the next set of experiments, synaptic strength was analysed in terms of AMPA/NMDA ratio. After the whole-cell configuration was made, excitatory postsynaptic currents (EPSCs) were evoked by focal extracellular stimulation every 5 s (0.5 Hz) at a holding potential of À60 mV in the presence of bicuculline (10 mM) and strychnine (0.5 mM) to block GABA A -and glycine receptor-mediated current components, respectively. The holding potential was then changed to + 40 mV, so that EPSC currents became outward rather than inward. Bath application of D-AP5, an NMDA receptor blocker (25 mM), reduced the slow component of the outward currents. The remaining fast components were blocked by additional application of CNQX (5 mM), an AMPA/kainite receptor blocker, suggesting the remaining fast components are non-NMDA (AMPA) receptor-mediated EPSCs. NMDA-receptor mediated synaptic current components were then obtained by electrically subtracting the average of 10 consecutive currents after application of D-AP5 from those before D-AP5 application (Fig. 6C) (Hamada et al., 2016) . The AMPA/NMDA ratio was then calculated to be 0.38 AE 0.33 (n = 7) and 0.52 AE 0.08 (n = 11) for control and the knockdown neurons, respectively, and the distribution is shown in Fig. 6D . Although the ratio in the knockdown cells tended to be much larger than that in control, this difference was not significant (P = 0.12), apparently because of the wide distribution of values in the knockdown cells (Fig. 6D) . We assume that this broad distribution reflects the extent of Phactr1-knockdown, which depends on the amount of the RNAi vector incorporated into individual neurons.
Discussion
West syndrome is an infantile epilepsy highly associated with cognitive impairment, autism and movement disorders. While West syndrome has multiple causes, disrupted corticogenesis with aberrant synaptic function produced by gene abnormalities is considered to be the major factor that underlies the pathogenesis and pathophysiology . In the present study, we identified by whole-exome sequencing two unreported de novo missense mutations, c.1449T 4 C/p. (Leu500Pro) (C) Representative data of AMPA-and NMDA-receptor-mediated synaptic currents evoked at + 40 mV. Mixed EPSCs were evoked by focal extracellular stimulation every 5 s (0.5 Hz) at a holding potential of À60 mV in the presence of bicuculline (10 mM) and strychnine (0.5 mM) to block GABA A -and glycine receptor-mediated current components, respectively. After the holding potential was changed to + 40 mV, D-AP5, an NMDA receptor blocker (25 mM), was applied in the bath. The remaining fast components were blocked by additional application of CNQX (5 mM), an AMPA/kainite receptor blocker, suggesting the remaining fast components are non-NMDA (AMPA) receptor-mediated EPSCs. NMDAreceptor-mediated synaptic current components were then obtained by electrically subtracting the average of 10 consecutive currents after application of D-AP5 from those before the application. (D) Distribution of AMPA/NMDA ratio. AMPA/NMDA ratios in control and knockdown neurons were 0.38 AE 0.33 (n = 7) and 0.52 AE 0.08 (n = 11), respectively. These values were not statistically different (P = 0.12). Matsuoka et al., 2015) , the patients in this study have not so far presented symptoms of cardiovascular diseases, but may have such potential risks in the future.
It should be noted that, we showed the c.1561C 4 T/ p.(Arg521Cys) mutation, which was reported as a de novo mutation in a female with infantile epilepsy and severe psychomotor delay (de Ligt et al., 2012) , could cause aberrant phenotypes similar to the other three mutations but it was found in four out of 123 080 individuals on the Genome Aggregation Database (gnomAD) database (Lek et al., 2016) . The gnomAD database is confederation of genome sequence data from population genetic studies and various disease-specific studies including schizophrenia, bipolar disorder and migraine, but data from individuals with 'severe pediatric disease' and their first-degree relatives have been excluded. This finding might imply that this mutation may be unable to cause severe epilepsy such as West syndrome. As for the reason for this discrepancy, we speculated that the functional impairment of PHACTR1 by this mutation might not always cause severe types of epilepsies (including West syndrome) due to incomplete penetrance in these four individuals of gnomAD. Alternatively, it may be possible that mild psychiatry phenotypes could be recognized in these individuals. It is well known that mutations in the same causative gene can exhibit various and broad clinical phenotypes. For instance, mutations in SCN1A gene will cause generalized epilepsy with febrile seizures plus, familial hemiplegic migraine or Dravet syndrome in different individuals (Escayg and Goldin, 2010; Meng et al., 2015) . More cases harbouring PHACTR1 abnormalities are essential to address this issue.
As for the molecular mechanism of the PHACTR1 mutations, we found that Phactr1-LP, Phactr1-NI and Phactr1-IN showed impaired interaction with actin while Phactr1-RC had little affinity for PP1. These four mutations, however, gave rise to similar aberrant phenotypes, especially in cortical neuron migration. From the results obtained in this study, impaired interactions of the RPEL domain with G-actin are likely to dysregulate local actin dynamics and disrupt the function of the actin cytoskeleton, leading to defects in neuronal migration and morphology. On the other hand, PP1 also plays essential roles in neuronal migration and synaptic plasticity (Ouimet et al., 1995; Yan et al., 1999; Ceulemans and Bollen, 2004) . Coordinated interactions with actin and PP1 may be essential for PHACTR1 function(s). Alternatively, actin-binding to PHACTR1 may subsequently influence its interaction with PP1 and vice versa. In either case, PHACTR1 is thought to be a pivotal scaffold for cortical neuron migration and synapse network formation during brain development. In addition, it is to be noted that PHACTR1 interacts with Slack (KCNT1, KNa1.1) potassium channel (Fleming et al., 2016) . Mutations in this channel have been shown to cause severe early-onset epileptic encephalopathies such as malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy and Ohtahara syndrome, all of which are associated with severe intellectual disability (Barcia et al., 2012; Heron et al., 2012; Martin et al., 2014) . Given that Slack mutations enhance Slack channel activity Tang et al., 2016) , PHACTR1 may physiologically regulate Slack channel function, and the PHACTR1 mutations analysed here may potentially also abnormally activate Slack channels.
The electrophysiological experiments have shown that there are significant differences in membrane resistance and firing patterns between control and Phactr1-knockdown neurons, although membrane capacitance and resting membrane potential were not significantly altered. The smaller number of action potentials elicited in Phactr1-silenced pyramidal neurons suggests that defective PHACTR1 function reduces neuronal excitability. In contrast, synaptic strength measured as the AMPA/NMDA ratio of evoked EPSCs was not statistically different between control and the knockdown neurons, although the ratio tended to be larger in the knockdown cells than control ones. The amount of sh-Phactr1#1 incorporated into cells during in utero electroporation may differ from neuron to neuron, and thus this may cause the broad range of observed AMPA/NMDA ratios in Phactr1-deficient neurons. We propose, however, that intrinsic membrane excitability becomes altered rather than excitatory inputs to pyramidal neurons. These electrophysiological findings may also contribute to the observed morphological abnormalities.
Epilepsy-implicated genes are generally associated with other neurodevelopmental and neuropsychiatric disorders (Brooks-Kayal, 2010) . For example, RBFOX1 (encoding a splicing regulator), STXBP1/MUNC18-1 (encoding a regulator of the neurotransmitter release) and AUTS2 (encoding a transcription factor) have been shown to be causative for not only epilepsy but also ASD and schizophrenia (Hamdan et al., 2011; Oksenberg and Ahituf, 2013; Bill et al., 2014) . Structural and/or functional defects in synapses may underlie the above diseases, because the above gene products, like PHACTR1, are distributed at synapses (Ito et al., 2018) . Nevertheless, the underlying molecular mechanisms causing synaptic dysfunction may depend on the specific gene abnormality. In case of PHACTR1, although the phenotypes of the mutations on dendrite development appeared to be similar ( Fig. 6A and  B) , the specific mechanisms are likely to be mutation-dependent, because Phactr1-LP, Phactr1-NI and Phactr1-IN are unstable in cortical neurons at P7 when compared to the wild-type and Phactr1-RC.
Based on the similarity in abnormal migration and morphological phenotypes associated with Phactr1-LP, Phactr1-NI, Phactr1-RC and Phactr1-IN, we assume that the pathophysiological background of West syndrome at least partially overlaps with that of psychomotor delay including intellectual disability. From the observed migration phenotypes of the mutants, the molecular mechanism of the PHACTR1 mutations is likely to involve dominant negative effects of the mutant allele. Considering the aberrant migration and morphological phenotypes of Phactr1-knockdown neurons, further genetic analyses may identify novel PHACTR1 abnormalities with haploinsufficiency.
PHACTR4 has been reported to be critical for the spatial and temporal regulation of neurulation (a folding process in vertebrate embryos including the transformation of the neural plate into the neural tube) through regulation of the cell cycle as well as PP1 activity (Kim et al., 2007) . PHACTR1 exhibited nucleocytoplasmic shuttling in a small GTPase Rho-and actin signalling-mediated manner in fibroblast NIH3T3 cells (Wiezlak et al., 2013) . Because PHACTR1 is localized at nuclei of cortical neurons from embryonic to adult stages (Ito et al., 2018) , the nuclear function of PHACTR1 in neuronal cells is an issue for future studies. In this context, neither PHACTR1 itself nor the two mutants (Phactr1-LP and Phactr1-RC) appear to be involved in neurogenesis during corticogenesis, since silencing of PHACTR1 as well as overexpression of PHACTR1 or the mutants had no effects on G1 cell cycle progression in the ventricular zone cells. PHACTR1 may modulate the growth and differentiation of cortical neurons through the fine tuning of transcription and/or translation rather than the regulation of cell cycle per se.
In this study, we identified two PHACTR1 mutations in West syndrome patients, and then clarified that PHACTR1 regulates cortical neuron morphology and migration as well as synaptic network formation and function during brain development. Functional defects of PHACTR1 are most likely to cause West syndrome and other neurodevelopmental disorders. Rapidly accumulating evidence indicates that typical infantile spasms are a genetically heterogeneous condition based on abnormalities in key brain development pathways. Because West syndrome-associated genes may account for at least 10% of these patients (McTague et al., 2016) , many other West syndrome-causative genes are expected to be identified. Considering that novel gene abnormalities found in patients may provide significant new insights into the molecular mechanisms of diseases, evolving genetic data on West syndrome may contribute to a reassessment of this disorder and may lead to novel targets for drug intervention aimed at interfering with the disease mechanisms.
